MD Anderson Inflammatory Breast Cancer Multi-Team Clinic, and Other Program Improvements.

Many exciting changes have been initiated within the past few months within the MD Anderson Morgan Welch IBC Research Program and Clinic. Patients are the most important people in our IBC Program, and we value the feedback they are able to provide. The first of these changes happened in May, 2015 and have continued to have a positive impact on patient satisfaction.

We started a pilot process on May 1, 2015 to have a dedicated IBC Ambassador available for patients’ questions and concerns. Our IBC Patient Ambassador assists in getting new patients in quickly, and contacts new patients before arrival to make their first day at MD Anderson as stress free as possible. The main goal of our IBC Patient Ambassador is to reduce the amount of time between our initial contact with a patient, and when they are seen at MD Anderson. They will also meet with each new and current IBC patient to inform them about our program, available clinical trials, and treatment approaches of the IBC Clinic. Although this process began as a pilot, we have had major success and have continued to reduce the amount of time between contact and appointments, while increasing the number of newly diagnosed IBC patients seen on a monthly basis.

Our IBC Multi-Team Clinic also began as a pilot process, with our first patient being seen in August, 2015. The IBC Multi-Team Clinic is the only multidisciplinary clinic in the United States that focuses on patients who are newly diagnosed with inflammatory breast cancer and are evaluated by our multidisciplinary team, in the same clinic, and within the same time frame. Our IBC Multi-Team Clinic focuses on patients who have been newly diagnosed with IBC; these patients can be treated or untreated, and metastatic or non-metastatic.

Our multidisciplinary team of IBC Specialists includes Dr. Naoto Ueno and Dr. Bora Lim – Breast Medical Oncology, Dr. Wendy Woodward and Dr. Welela Tereffe – Radiation Oncology and Dr. Anthony Lucci and Dr. Sarah DeSnyder.
– Surgical Oncology. During the appointment, treatment plans are discussed and determined by our group of IBC Specialists.

We are currently seeing one patient per week to pilot the IBC Multi-Team Clinic; an increase in appointments will be determined by the number of newly diagnosed patients requesting Multi-Team appointments. It is important to note that our IBC Specialists will continue to see patients with IBC who are new to MD Anderson, as well as their current patients, in a non-IBC Multi-Team Clinic setting. The quality of care does not differ between the IBC Multi-Team Clinic and our regular IBC Clinic, the only difference between clinics will be the timing of appointments with our IBC Specialists.

We look forward to receiving feedback on these changes, as well as others we are hoping to implement in the future. We enjoy hearing good feedback, along with improvements that could be made. Should you have any ideas or suggestions, please don’t hesitate to reach out to our group. We truly enjoy partnering with our patients for the betterment of our Program and Clinic.

Quarterly Oral Presentations

**Development of a microfluidic system for the isolation and molecular characterization of circulating tumor cells**
Hui Gao, PhD
Senior Research Scientist
Gitanjali Jayachandran, PhD
Senior Research Scientist

**Fluid Phase of Solid Tumors: Single Cell Biology**
Peter Kuhn, PhD
Dean's Professor of Biological Sciences
Professor of Medicine, Biomedical Engineering, and Aerospace & Mechanical Engineering
University of Southern California

**EGFR/COX-2 signaling regulating cancer stem cells in inflammatory breast cancer through TGF beta/Nodal pathway**
Xiaoping Wang, PhD
Research Scientist, Breast Medical Oncology

**Blocking TH2 Cytokine Signaling with Small Molecule Phosphopeptide Mimetics Targeting STAT6**
John McMurray, PhD
Associate Professor, Experimental Therapeutics

Recent Publications

**Circulating tumor cells in newly diagnosed inflammatory breast cancer**
James Reuben, PhD
View article here: [http://1.usa.gov/1KxY99q](http://1.usa.gov/1KxY99q)

**Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells**
James Reuben, PhD
View article here: [http://1.usa.gov/1V7XvKU](http://1.usa.gov/1V7XvKU)

**Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer**
Anthony Lucci, MD
View article here: [http://1.usa.gov/1KuYugc](http://1.usa.gov/1KuYugc)

**Detection and enumeration of circulating tumor cells based on their invasive property**
Xiangwei Wu, PhD
View article here: [http://1.usa.gov/1gKeBvI](http://1.usa.gov/1gKeBvI)

**MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in triple-negative breast cancer xenograft model**
Naoto Ueno, MD, PhD
View article here: [http://1.usa.gov/1Ffn1XJ](http://1.usa.gov/1Ffn1XJ)

**Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis**
Naoto Ueno, MD, PhD
View article here: [http://1.usa.gov/1G2HFVL](http://1.usa.gov/1G2HFVL)
Recent Publications Continued

Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model
Wendy Woodward, MD, PhD
View article here: http://1.usa.gov/1L671cN

High density and very low density lipoprotein have opposing roles in regulating tumor initiating cells and sensitivity to radiation in inflammatory breast cancer
Wendy Woodward, MD, PhD
View article here: http://1.usa.gov/1ORO3qa

Current Clinical Trials Open for New Patient Enrollment

2006-1072  IBC Registry
2010-0842  A phase I Entinostat and Lapatinib + Herceptin HER2+ MBC failed Herceptin
2013-0007  Phase II study of denosumab to define the role of bone related biomarkers in patients with breast cancer and bone metastasis
2013-0139  Phase IB trial of two folate binding protein peptide vaccine (E39 and J65) in breast and ovarian cancer patients
2013-0436  Combination immunotherapy with Herceptin and HER2 vaccine E75 in low and intermediate HER2 expressing breast cancer patients to prevent recurrence
2014-0464  A phase II study of BIBF-1120 (Nintedanib) for patients with HER2 normal metastatic inflammatory breast cancer
2014-0533  A phase II study of anti-PD1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer who have received prior chemotherapy with clinical response

Current Lab Studies

PA12-0097  Prognostic Utility of CTCs Assessed by Adnagen Technology and Clinical Outcome of Patients with Stage III Breast Cancer
PA12-0453  EpCAM-CTC-EMT
PA12-0860  Assessing feasibility of sentinel lymph node increase dissection in IBC
PA14-0772  Deviation of patient derived xenograft tumor models from isolated CTC from breast cancer patients (IBC/TNBC)
PA14-0778  Gene profiles in androgen receptor-positive CTC in patients with metastatic breast cancer

If you are interested in learning more about our clinical trials, or lab studies, please email the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic directly at ibcp@mdanderson.org. We are happy to provide general information and eligibility guidelines for our clinical trials and lab studies.